N-(3-Pyridazinyl)ethylenediamine | 193473-68-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(3-Pyridazinyl)ethylenediamine
• 英文别名: N-(2-aminoethyl)pyridazin-3-amine；N'-pyridazin-3-ylethane-1,2-diamine
• CAS: 193473-68-6
• 化学式: C₆H₁₀N₄
• mdl: MFCD16767528
• 分子量: 138.172
• InChiKey: WADBRFVVWDZQLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  383.0±22.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Bis-heteroaryl derivatives as modulators of protein aggregation
  申请人：UCB Biopharma SRL

  公开号：US10913735B2

  公开（公告）日：2021-02-09

  The present invention relates to bis-heteroaryl compounds of formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

  本发明涉及式（I）的双杂芳基化合物、含有它们的药物组合物以及使用它们的方法，包括预防、逆转、减缓或抑制蛋白质聚集的方法，以及治疗与蛋白质聚集有关的疾病的方法、包括神经退行性疾病，如帕金森病、阿尔茨海默病、路易体病、帕金森病伴痴呆症、额颞叶痴呆症、亨廷顿氏病、肌萎缩性脊髓侧索硬化症和多系统萎缩，以及癌症，包括黑色素瘤。
• EP0906103A4
  申请人：——

  公开号：EP0906103A4

  公开（公告）日：1999-04-07
• VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0906103A1

  公开（公告）日：1999-04-07
• US6159964A
  申请人：——

  公开号：US6159964A

  公开（公告）日：2000-12-12
• [EN] VITRONECTIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE LA VITRONECTINE
  申请人：——

  公开号：WO1997024124A1

  公开（公告）日：1997-07-10

  [EN] Compounds of formula (I) are disclosed, wherein: A is a fibrinogen antagonist template; W is a linking moiety of the form -(CHR)a-U-(CHR)b-V-; Q<1>, Q<2>, Q<3> and Q<4> are independently N or C-R, provided that no more than one of Q<1>, Q<2>, Q<3> and Q<4> is N; R' is H or C1-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar-C0-6alkyl; R is H or C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar-C0-6alkyl; R is R, -C(O)R or -C(O)OR R is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, Ar-C0-6alkyl, Het-C0-6alkyl-U'-C1-6alkyl, C3-7cycloalkyl-C0-6alkyl-U'-C1-6alkyl or Ar-C0-6alkyl-U'-C1-6alkyl; R is H, halo, -OR, -SR, -CN, -NRR, -NO2, -CF3, CF3S(O)r-, -CO2R, -COR or -CONR2, or C1-6alkyl optionally substituted by halo, -OR, -SR, -CN, -NRR'', -NO2, -CF3, R'S(O)3-, -CO2R, -COR or -CONR2; U and V are absent or CO, CR2, C(=CR2), S(O)c, O, NR, CROR, CR(OR)CR2, CR2CR(OR), C(O)CR2, CR2C(O), CONR, NRCO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR, NRC(S), S(O)2NR, NRS(O)2N=N, NRNR, NRCR2, NRCR2, CR2O, OCR2, CR=CR, CC, Ar or Het; a is 0, 1, 2 or 3; b is 0, 1 or 2; c is 0, 1 or 2; r is 0, 1 or 2; and u is 0 or 1; or pharmaceutically acceptable salts thereof, which are vitronectin receptor antagonists useful in the treatment of osteoporosis.
  [FR] La présente invention concerne des composés de la formule (I), dans laquelle A est une matrice d'antagoniste fibrinogène; W est un fragment de liaison dont la forme est -(CHR)a-U-(CHR)b-V-; Q<1>, Q<2>, Q<3> et Q<4> sont, de manière indépendante, N (au maximum l'un d'entre eux) ou C-R; R' est H ou alkyle C1-6, cycloalkyle C3-7-alkyle C0-6 ou Ar-alkyle C0-6, R est H ou alkyle C1-6, Het-alkyle C0-6, cycloalkyle C3-7-alkyle C0-6 ou Ar-alkyle C0-6; R est R, -C(O)R ou -C(O)OR, R est H, alkyle C1-6, Het-alkyle C0-6, cycloalkyle C3-7-alkyle C0-6, Ar-alkyle C0-6, Het-alkyle C0-6-U'-alkyle C1-6, cycloalkyle C3-7-alkyle C0-6-U'-alkyle C1-6 ou Ar-alkyle C0-6-U'-alkyle C1-6; R est H, halo, -OR, -SR, -CN, -NRR, -NO2, -CF3, CF3S(O)r-, -CO2R, -COR ou -CONR2, ou alkyle C1-6 facultativement substitué par halo, -OR, -SR, -CN, -NRR'', -NO2, -CF3, R'S(O)3-, -CO2R ou -CONR2; U and V sont absents ou CO, CR2, C(=CR2), S(O)c, O, NR, CROR, CR(OR)CR2, CR2CR(OR), C(O)CR2, CR2C(O), CONR, NRCO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR, NRC(S), S(O)2NR, NRS(O)2N=N, NRNR, NRCR2, NRCR2, CR2O, OCR2, CR=CR, CC, Ar ou Het; a vaut 0, 1, 2 ou 3; b vaut 0, 1 ou 2; c vaut 0, 1 ou 2; r vaut 0, 1 ou 2; et u est 0 ou 1. L'invention concerne aussi des sels de ces composés acceptables sur le plan pharmacologique qui sont des antagonistes de récepteurs de la vitronectine utiles dans le traitement de l'ostéoporose.